Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tenax Therapeutics (TENX)

Tenax Therapeutics (TENX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,210
  • Shares Outstanding, K 6,244
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,600 K
  • EBIT $ -47 M
  • EBITDA $ -47 M
  • 60-Month Beta 1.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.26
  • Number of Estimates 4
  • High Estimate -0.41
  • Low Estimate -3.80
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.94 +46.78%
on 01/02/26
18.38 -12.68%
on 01/14/26
+4.89 (+43.82%)
since 12/16/25
3-Month
6.10 +163.03%
on 10/21/25
18.38 -12.68%
on 01/14/26
+9.23 (+135.34%)
since 10/16/25
52-Week
4.63 +246.65%
on 04/22/25
18.38 -12.68%
on 01/14/26
+9.64 (+150.59%)
since 01/16/25

Most Recent Stories

More News
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half...

TENX : 16.05 (+0.94%)
Tenax Therapeutics to Participate in Upcoming Investor Conferences

CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using...

TENX : 16.05 (+0.94%)
Tenax Therapeutics: Q3 Earnings Snapshot

Tenax Therapeutics: Q3 Earnings Snapshot

TENX : 16.05 (+0.94%)
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2,...

TENX : 16.05 (+0.94%)
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using...

TENX : 16.05 (+0.94%)
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using...

TENX : 16.05 (+0.94%)
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF ...

TENX : 16.05 (+0.94%)
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using...

TENX : 16.05 (+0.94%)
Tenax Therapeutics: Q2 Earnings Snapshot

Tenax Therapeutics: Q2 Earnings Snapshot

TENX : 16.05 (+0.94%)
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2,...

TENX : 16.05 (+0.94%)

Business Summary

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The Company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, and liquid ventilation...

See More

Key Turning Points

3rd Resistance Point 18.08
2nd Resistance Point 17.36
1st Resistance Point 16.71
Last Price 16.05
1st Support Level 15.34
2nd Support Level 14.62
3rd Support Level 13.97

See More

52-Week High 18.38
Last Price 16.05
Fibonacci 61.8% 13.13
Fibonacci 50% 11.50
Fibonacci 38.2% 9.88
52-Week Low 4.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar